Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seems to be holding steady so far today. That's a good sign given the huge volume of shares traded last week. I wonder if PLX has even more good news they will share at the upcoming conference.
That’s true. People who have been stuck for years get a chance to unload.
That's possible. Another possibility is that the leader of the many pump and dump groups out there picked up his/her shares and will now tell their followers to start buying. After they're all done buying they start the pump while dumping their shares. I don't know why the SEC doesn't shut down those groups. They are manipulating the stock price.
Protalix up 20% on positive PRX-102 data in Fabry
https://seekingalpha.com/news/3392180-protalix-20-percent-positive-prxminus-102-data-fabry
They don’t start pumping until after they have the shares they want. Then they pump while they’re selling their shares. Classic.
Yeah. Maybe Verizon will start giving new customers free marijuana with every new phone line.
Unfortunately it won’t have anything to do with RMTD shareholders since Telogis never purchased RMTD shares, only the assets.
Then why no attorney letter after all this time. We’ll be coming up on a year since the first filings.
Why wouldn’t they unless this is all a scam.
but they can't seem to get an attorney to sign off on them. I wonder why.
0.725 should have held onto those shares.
I don't think anyone predicted this would go back down to 003 during that last spike. And the company hasn't explained why they called off the reverse split. It looks like any deal in the works got cancelled.
too late, I've already started celebrating.
it's acting like it wants to go back to triple 0's
What are we waiting to see by end of day?
so do you. I'm basing decisions on what has happened to date. You can as well.
Protalix BioTherapeutics Due Off Halt at 1110 AM ET, Says Fabry Disesase Treatment Study Data Positive So Far
11:12 AM EDT, 09/21/2018 (MT Newswires) -- Protalix BioTherapeutics (PLX) shares are halted. The company said preliminary data from the BRIDGE study of pegunigalsidase alfa (PRX-102) to treat Fabry disease in 16 patients demonstrated an improvement in kidney function when switched to pegunigalsidase alfa (PRX-102) from agalsidase alfa (Replagal).
The BRIDGE study is an open-label, single arm switch-over study to assess the safety and efficacy of pegunigalsidase alfa, 1 mg/kg infused every two weeks, in 22 Fabry patients currently treated with Replagal. Protalix anticipates completing patient enrollment in the BRIDGE trial in Q4.
PRX-102 is the company's plant cell-expressed recombinant, PEGylated, cross-linked -galactosidase-A for Fabry disease. In pre-clinical and clinical studies, PRX-102 demonstrated higher stability in plasma, a longer half-life and higher exposure in Fabry disease patients, and a reduction in Gb3 in kidney biopsies in treatment na ve Fabry patients, the company said.
that doesn't seem like a wise move. all good news in the pipeline. I expect we'll see much more institutional investment.
Wow. Volume spiking. Price hit 74 in wild trading.
If not an acquisition perhaps they’re raising money to pay licensing fees they owe to hdvy.
Speaking of which does anyone know if hdvy has filed a lawsuit against neo for damages?
I’m encouraged by today’s trading. I thought we might see more profit taking but so far the price has held up well.
Most likely good news coming from the BRIDGE trials.
over 2 million shares and still going. news must be leaking.
I think milestone 1 should have been completed by now. I hope it's not a bad sign.
why sell? it's on a roll
is this still a corpse?
still short?
Over 60 cents for the first time in awhile. Hopefully this is just the beginning of a major reversal with BRIDGE results as the first catalyst.
Must be some good results coming on the bridge study
Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
https://finance.yahoo.com/news/protalix-biotherapeutics-present-preliminary-data-110000758.html
You’re right. There are a bunch of filings. It’s good they have incentive for the stock price to increase. If the trials are positive it should increase far beyond the strike price.
Yeah. As in go down even further. Is this now the lowest price stock on the planet? Too many 0’s to count.
The share price tells you all you need to know. And it stays there year after year after year. After a record bull market think if the lost opportunity from dead money in these POS shares. Lol
Looks like they gave the CFO 70,000 options to buy shares at $0.56 per share, with expiration date of 2028. It's a decent bet that they will be worth much more than that sometime in the next 10 years.
If that were the case the stock price should be rising, not falling.
the elephant in the room is why did they announce a reverse split and then drop it with no explanation. That looks like a cancelled deal.
that's over 2 years old. hmmmm
Looks like we’re finally on a roll. We’ll see.
Not me. And the silence doesn’t seem like a good sign. Do we even know if any lawsuits are progressing?
Amazing volume today.
I took a look at the average cost for 2 competing treatments -- Fabrazyme and Galafold. They each cost anywhere from $200,000 to $300,000 per year, depending on the country (lower end in Europe and higher end in the US).
Assuming approval, it will be interesting to see what PLX's strategy is for pricing PRX-102. Do they charge more because the treatment is superior to existing, or less to give insurance companies an incentive to cover it vs. the other treatments?
Or perhaps it's entirely up to Chiesi to set the prices.
https://www.reuters.com/article/us-amicus-fda/amicus-sets-315000-price-for-new-fabry-disease-treatment-idUSKBN1KY1E8